Cerity Partners LLC Sells 15,537 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Cerity Partners LLC lowered its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 47.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 17,359 shares of the biopharmaceutical company's stock after selling 15,537 shares during the quarter. Cerity Partners LLC's holdings in Royalty Pharma were worth $459,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Keene & Associates Inc. boosted its stake in Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock valued at $495,000 after buying an additional 370 shares during the period. National Bank of Canada FI boosted its position in shares of Royalty Pharma by 21.8% during the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 371 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 376 shares in the last quarter. Sanctuary Advisors LLC increased its position in shares of Royalty Pharma by 0.9% in the fourth quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock worth $1,068,000 after purchasing an additional 388 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in Royalty Pharma by 0.5% during the fourth quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company's stock valued at $2,822,000 after purchasing an additional 537 shares during the last quarter. Institutional investors own 54.35% of the company's stock.

Analyst Ratings Changes

Separately, Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $42.50.

Royalty Pharma Trading Up 0.5 %

Shares of RPRX stock traded up $0.17 on Friday, hitting $32.20. 3,442,452 shares of the company's stock traded hands, compared to its average volume of 3,253,767. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a market capitalization of $18.56 billion, a price-to-earnings ratio of 22.21, a P/E/G ratio of 2.31 and a beta of 0.50. The company's fifty day simple moving average is $32.52 and its 200 day simple moving average is $29.42. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Equities analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.73%. Royalty Pharma's dividend payout ratio is currently 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.